5-(4-cyclobutyl-piperazine-1-carbonyl)-1H-indole-2-carboxylic acid ethyl ester | 952797-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-(4-cyclobutyl-piperazine-1-carbonyl)-1H-indole-2-carboxylic acid ethyl ester
• 英文别名: ethyl 5-(4-cyclobutylpiperazine-1-carbonyl)-1H-indole-2-carboxylate
• CAS: 952797-82-9
• 化学式: C₂₀H₂₅N₃O₃
• 分子量: 355.437
• InChiKey: YNBZSMUWLSQPLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  65.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(4-cyclobutyl-piperazine-1-carbonyl)-1H-indole-2-carboxylic acid ethyl ester 在 lithium hydroxide monohydrate 、 水 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 以100%的产率得到5-(4-cyclobutyl-piperazine-1-carbonyl)-1H-indole-2-carboxylic acid hydrochloride/lithium chloride complex
  参考文献：
  名称：

  5-Hydroxyindole-2-carboxylic Acid Amides: Novel Histamine-3 Receptor Inverse Agonists for the Treatment of Obesity

  摘要：

  Obesity is a major risk factor in the development of conditions such as hypertension, hyperglycemia, dyslipidemia, coronary artery disease, and cancer. Several pieces of evidence across different species, including primates, underscore the implication of the histamine 3 receptor (H3R) in the regulation of food intake and body weight and the potential therapeutic effect Of H3R inverse agonists. A pharmacophore model, based on public information and validated by previous investigations, was used to design several potential scaffolds. Out of these scaffolds. the 5-hydroxyindole-2-carboxylic acid amide appeared to be of great potential as a novel series of H-3 inverse agonist. Extensive structure-activity relationships revealed the interconnectivity of microsomal clearance and hERG (human ether-a-go-go-related gene) affinity with lipophilicity, artificial membrane permeation, and basicity. This effort led to the identification of compounds reversing the (R)-alpha-methylhistamine-induced water intake increase in Wistar rats and, further, reducing food intake in diet-induced obese Sprague-Dawley rats. Of these, the biochemical, pharmacokinetic, and pharmacodynamic characteristics of (4,4-difluoropiperidin-1-yl)[1-isopropyl-5-(1-isopropylpiperidin-4-yloxy)1H-indol-2-yl]-methanone 36 are detailed.

  DOI：

  10.1021/jm900409x
• 作为产物：
  描述：

  1-cyclobutylpiperazine dihydrochloride 、 2-乙氧基羰基-5-吲哚羧酸 在 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.67h， 以63%的产率得到5-(4-cyclobutyl-piperazine-1-carbonyl)-1H-indole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  5-Hydroxyindole-2-carboxylic Acid Amides: Novel Histamine-3 Receptor Inverse Agonists for the Treatment of Obesity

  摘要：

  Obesity is a major risk factor in the development of conditions such as hypertension, hyperglycemia, dyslipidemia, coronary artery disease, and cancer. Several pieces of evidence across different species, including primates, underscore the implication of the histamine 3 receptor (H3R) in the regulation of food intake and body weight and the potential therapeutic effect Of H3R inverse agonists. A pharmacophore model, based on public information and validated by previous investigations, was used to design several potential scaffolds. Out of these scaffolds. the 5-hydroxyindole-2-carboxylic acid amide appeared to be of great potential as a novel series of H-3 inverse agonist. Extensive structure-activity relationships revealed the interconnectivity of microsomal clearance and hERG (human ether-a-go-go-related gene) affinity with lipophilicity, artificial membrane permeation, and basicity. This effort led to the identification of compounds reversing the (R)-alpha-methylhistamine-induced water intake increase in Wistar rats and, further, reducing food intake in diet-induced obese Sprague-Dawley rats. Of these, the biochemical, pharmacokinetic, and pharmacodynamic characteristics of (4,4-difluoropiperidin-1-yl)[1-isopropyl-5-(1-isopropylpiperidin-4-yloxy)1H-indol-2-yl]-methanone 36 are detailed.

  DOI：

  10.1021/jm900409x
• 作为试剂：
  描述：

  2-乙氧基羰基-5-吲哚羧酸 、 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate 、 1-环丁基哌嗪 、 N,N-二异丙基乙胺 在 5-(4-cyclobutyl-piperazine-1-carbonyl)-1H-indole-2-carboxylic acid ethyl ester 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以to give the desired product as a light brown solid (62%)的产率得到5-(4-cyclobutyl-piperazine-1-carbonyl)-1H-indole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  5-amido-indole-2-carboxamide derivatives

  摘要：

  本发明涉及式I的化合物，其中G和R1到R5和R12在说明书和权利要求书中定义，以及其药学上可接受的盐。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。

  公开号：

  US07601711B2

文献信息

• 5-AMIDO-INDOLE-2-CARBOXAMIDE DERIVATIVES
  申请人：Nettekoven Matthias

  公开号：US20090264418A1

  公开（公告）日：2009-10-22

  The present invention relates to compounds of formula I wherein G and R 1 to R 5 and R 12 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及公式I的化合物，其中G和R1到R5和R12如描述和要求中所定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
• 5-AMIDO-2-CARBOXAMIDE INDOLES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2010487A1

  公开（公告）日：2009-01-07
• US7601711B2
  申请人：——

  公开号：US7601711B2

  公开（公告）日：2009-10-13
• US7723325B2
  申请人：——

  公开号：US7723325B2

  公开（公告）日：2010-05-25
• [EN] 5-AMIDO-2-CARBOXAMIDE INDOLES<br/>[FR] 5-AMIDO-2-CARBOXAMIDE INDOLES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2007115938A1

  公开（公告）日：2007-10-18

  [EN] The present invention relates to compounds of formula (I) wherein G and R to R and R are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
  [FR] La présente invention concerne des composés répondant à la formule (I), G et R1 à R5 et R12 étant tels qu'ils sont définis dans la description et les revendications, et des sels pharmaceutiquement acceptables desdits composés. Les composés sont utiles pour le traitement et/ou la prévention de maladies qui sont associées avec la modulation des récepteurs H3.